Transplant international : official journal of the European Society for Organ Transplantation · 2026
Institut Georges Lopez-2M as a Novel Lung Preservation Solution Attenuates Ischemia-Reperfusion Injury in a Rat Ex Vivo Lung Perfusion Model.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Barbarossa Annalisa, Van Slambrouck Jan, Trivett Cara, Kortleven Phéline, Vanluyten Cedric, Medina Alberto Martin, Jin Xin, Jannis Nicole, Özsoy Balin, Claes Sandra, Schols Dominique, Wylin Tine, Moermans Karen, Stegen Steve, Rosello Arnau Panisello, Inci Ilhan, De Leyn Paul, Vanaudenaerde Bart, Pirenne Jacques, Jones Elizabeth A V, Ceulemans Laurens J
Аннотация
Institut Georges Lopez-2M (IGL-2M), a novel preservation solution containing polyethylene glycol (PEG 35kD, 5 g/L), preserves mitochondrial integrity and redox balance in liver grafts. This study assesses IGL-2M's effect on lung preservation during prolonged cold ischemia. Rat's heart-lung blocks were procured and subjected to 18 h cold ischemia (4 °C). Lungs were flushed and preserved using one of these preservation solutions: OCS, Perfadex Plus, IGL-2M (n = 6/group). Following ischemia, lungs underwent up to 7 h normothermic ex vivo lung perfusion. Edema was quantified by weight gain. Lung physiological parameters were recorded. Perfusate, bronchoalveolar lavage (BAL), and tissue samples were collected. All lungs in IGL-2M group completed 7 h EVLP protocol. Compared to OCS, IGL-2M reduced edema formation (p < 0.01), preserved superior compliance (p < 0.01), and maintained lower pulmonary vascular resistance (p < 0.01). IGL-2M showed lower perfusate concentrations of IL-1β (p < 0.05), IL-6 (p < 0.05), and TNF-α (p = 0.08). In BAL, IGL-2M reduced IL-1β (p < 0.01), IL-6 (p < 0.05), TNF-α (p < 0.01), and CXCL1 (p < 0.01). IGL-2M showed lower release of Syndecan-1 (p < 0.05). Compared to Perfadex Plus, IGL-2M was not inferior, with reduced expression of TNF-α in the perfusate (p < 0.05). IGL-2M effectively prevents edema development like Perfadex Plus. IGL-2M results in decreased inflammation and a stronger endothelial lining, making it a promising solution for lung preservation.